Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.62 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.60 |
| ▸ | CFTR | P13569 | 11/20 | 0.58 |
| ▸ | DUSP22 | Q9NRW4 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791360 | 0.86 | MAP3K5 (0.66) | PTPN12PTPN22CFTRDUSP22MEN1 | |
| SCHEMBL6790545 | 0.85 | PTPN12 (0.77) | PTPN12PTPN22CFTRDUSP22MEN1 | |
| SCHEMBL6791582 | 0.84 | MEN1 (0.62) | PTPN12PTPN22CFTRDUSP22MEN1 | |
| SCHEMBL6784929 | 0.83 | PTPN12 (0.72) | PTPN12PTPN22DUSP22MEN1KMT2A | |
| SCHEMBL7168872 | 0.83 | PTPN12 (0.72) | PTPN12PTPN22DUSP22MEN1KMT2A | |
| SCHEMBL46216 | 0.83 | PTPN12 (0.77) | PTPN12PTPN22DUSP22MEN1KMT2A | |
| SCHEMBL6742617 | 0.83 | PTPN12 (0.77) | PTPN12PTPN22DUSP22MEN1KMT2A | |
| SCHEMBL6785407 | 0.83 | PTPN12 (0.61) | PTPN12PTPN22CFTRDUSP22MEN1 | |
| SCHEMBL6786253 | 0.83 | PTPN12 (0.66) | PTPN12PTPN22CFTRDUSP22MEN1 | |
| SCHEMBL6789461 | 0.82 | CFTR (0.61) | PTPN12PTPN22CFTRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | claimed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | claimed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | claimed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | disclosed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | TNFRSF1A 3580/4885PTPN12 3716/4885PTPN22 3567/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | TNFRSF1A 3580/4885PTPN12 3716/4885PTPN22 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.